|
1
|
Kumar V, Patel S, Tcyganov E and
Gabrilovich DI: The nature of myeloid-derived suppressor cells in
the tumor microenvironment. Trends Immunol. 37:208–220.
2016.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Gabrilovich DI: Myeloid-derived suppressor
cells. Cancer Immunol Res. 5:3–8. 2017.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Li K, Shi H, Zhang B, Ou X, Ma Q, Chen Y,
Shu P, Li D and Wang Y: Myeloid-derived suppressor cells as
immunosuppressive regulators and therapeutic targets in cancer.
Signal Transduct Target Ther. 6(362)2021.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Huang B, Pan PY, Li Q, Sato AI, Levy DE,
Bromberg J, Divino CM and Chen SH: Gr-1+CD115+ immature myeloid
suppressor cells mediate the development of tumor-induced T
regulatory cells and T-cell anergy in tumor-bearing host. Cancer
Res. 66:1123–1131. 2006.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Lee CR, Kwak Y, Yang T, Han JH, Park SH,
Ye MB, Lee W, Sim KY, Kang JA, Kim YC, et al: Myeloid-derived
suppressor cells are controlled by regulatory T cells via TGF-β
during murine colitis. Cell Rep. 17:3219–3232. 2016.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Chen JY, Lai YS, Chu PY, Chan SH, Wang LH
and Hung WC: Cancer-derived VEGF-C increases chemokine production
in lymphatic endothelial cells to promote CXCR2-dependent cancer
invasion and MDSC recruitment. Cancers (Basel).
11(1120)2019.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Yan HH, Pickup M, Pang Y, Gorska AE, Li Z,
Chytil A, Geng Y, Gray JW, Moses HL and Yang L: Gr-1+CD11b+ myeloid
cells tip the balance of immune protection to tumor promotion in
the premetastatic lung. Cancer Res. 70:6139–6149. 2010.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Kusmartsev S, Nefedova Y, Yoder D and
Gabrilovich DI: Antigen-specific inhibition of CD8+ T cell response
by immature myeloid cells in cancer is mediated by reactive oxygen
species. J Immunol. 172:989–999. 2004.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Ochoa AC, Zea AH, Hernandez C and
Rodriguez PC: Arginase, prostaglandins, and myeloid-derived
suppressor cells in renal cell carcinoma. Clin Cancer Res.
13:721s–726s. 2007.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Almand B, Clark JI, Nikitina E, van Beynen
J, English NR, Knight SC, Carbone DP and Gabrilovich DI: Increased
production of immature myeloid cells in cancer patients: A
mechanism of immunosuppression in cancer. J Immunol. 166:678–689.
2001.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Mirza N, Fishman M, Fricke I, Dunn M,
Neuger AM, Frost TJ, Lush RM, Antonia S and Gabrilovich DI:
All-trans-retinoic acid improves differentiation of myeloid cells
and immune response in cancer patients. Cancer Res. 66:9299–9307.
2006.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Alshetaiwi H, Pervolarakis N, McIntyre LL,
Ma D, Nguyen Q, Rath JA, Nee K, Hernandez G, Evans K, Torosian L,
et al: Defining the emergence of myeloid-derived suppressor cells
in breast cancer using single-cell transcriptomics. Sci Immunol.
5(eaay6017)2020.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Shou D, Wen L, Song Z, Yin J, Sun Q and
Gong W: Suppressive role of myeloid-derived suppressor cells
(MDSCs) in the microenvironment of breast cancer and targeted
immunotherapies. Oncotarget. 7:64505–64511. 2016.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Baert T, Vankerckhoven A, Riva M, Van
Hoylandt A, Thirion G, Holger G, Mathivet T, Vergote I and
Coosemans A: Myeloid derived suppressor cells: Key drivers of
immunosuppression in ovarian cancer. Front Immunol.
10(1273)2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Taki M, Abiko K, Baba T, Hamanishi J,
Yamaguchi K, Murakami R, Yamanoi K, Horikawa N, Hosoe Y, Nakamura
E, et al: Snail promotes ovarian cancer progression by recruiting
myeloid-derived suppressor cells via CXCR2 ligand upregulation. Nat
Commun. 9(1685)2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Filipazzi P, Valenti R, Huber V, Pilla L,
Canese P, Iero M, Castelli C, Mariani L, Parmiani G and Rivoltini
L: Identification of a new subset of myeloid suppressor cells in
peripheral blood of melanoma patients with modulation by a
granulocyte-macrophage colony-stimulation factor-based antitumor
vaccine. J Clin Oncol. 25:2546–2553. 2007.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Pandit R, Lathers DM, Beal NM, Garrity T
and Young MR: CD34+ immune suppressive cells in the peripheral
blood of patients with head and neck cancer. Ann Otol Rhinol
Laryngol. 109:749–754. 2000.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Lathers DM, Achille N, Kolesiak K, Hulett
K, Sparano A, Petruzzelli GJ and Young MR: Increased levels of
immune inhibitory CD34+ progenitor cells in the peripheral blood of
patients with node positive head and neck squamous cell carcinomas
and the ability of these CD34+ cells to differentiate into immune
stimulatory dendritic cells. Otolaryngol Head Neck Surg.
125:205–212. 2001.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Suzuki E, Kapoor V, Jassar AS, Kaiser LR
and Albelda SM: Gemcitabine selectively eliminates splenic
Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and
enhances antitumor immune activity. Clin Cancer Res. 11:6713–6721.
2005.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Blattner C, Fleming V, Weber R, Himmelhan
B, Altevogt P, Gebhardt C, Schulze TJ, Razon H, Hawila E, Wildbaum
G, et al: CCR5+ myeloid-derived suppressor cells are
enriched and activated in melanoma lesions. Cancer Res. 78:157–167.
2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Lin S, Wang J, Wang L, Wen J, Guo Y, Qiao
W, Zhou J, Xu G and Zhi F: Phosphodiesterase-5 inhibition
suppresses colonic inflammation-induced tumorigenesis via blocking
the recruitment of MDSC. Am J Cancer Res. 7:41–52. 2017.PubMed/NCBI
|
|
22
|
Kim K, Skora AD, Li Z, Liu Q, Tam AJ,
Blosser RL, Diaz LA Jr, Papadopoulos N, Kinzler KW, Vogelstein B
and Zhou S: Eradication of metastatic mouse cancers resistant to
immune checkpoint blockade by suppression of myeloid-derived cells.
Proc Natl Acad Sci USA. 111:11774–11779. 2014.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Steele CW, Karim SA, Leach JDG, Bailey P,
Upstill-Goddard R, Rishi L, Foth M, Bryson S, McDaid K, Wilson Z,
et al: CXCR2 inhibition profoundly suppresses metastases and
augments immunotherapy in pancreatic ductal adenocarcinoma. Cancer
Cell. 29:832–845. 2016.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Sun L, Clavijo PE, Robbins Y, Patel P,
Friedman J, Greene S, Das R, Silvin C, Van Waes C, Horn LA, et al:
Inhibiting myeloid-derived suppressor cell trafficking enhances T
cell immunotherapy. JCI Insight. 4(e126853)2019.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Youn JI, Collazo M, Shalova IN, Biswas SK
and Gabrilovich DI: Characterization of the nature of granulocytic
myeloid-derived suppressor cells in tumor-bearing mice. J Leukoc
Biol. 91:167–181. 2012.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Dufait I, Schwarze JK, Liechtenstein T,
Leonard W, Jiang H, Escors D, De Ridder M and Breckpot K: Ex vivo
generation of myeloid-derived suppressor cells that model the tumor
immunosuppressive environment in colorectal cancer. Oncotarget.
6:12369–12382. 2015.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Schröder M, Loos S, Naumann SK, Bachran C,
Krötschel M, Umansky V, Helming L and Swee LK: Identification of
inhibitors of myeloid-derived suppressor cells activity through
phenotypic chemical screening. Oncoimmunology.
6(e1258503)2016.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Marigo I, Bosio E, Solito S, Mesa C,
Fernandez A, Dolcetti L, Ugel S, Sonda N, Bicciato S, Falisi E, et
al: Tumor-induced tolerance and immune suppression depend on the
C/EBPbeta transcription factor. Immunity. 32:790–802.
2010.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Lechner MG, Megiel C, Russell SM, Bingham
B, Arger N, Woo T and Epstein AL: Functional characterization of
human Cd33+ and Cd11b+ myeloid-derived suppressor cell subsets
induced from peripheral blood mononuclear cells co-cultured with a
diverse set of human tumor cell lines. J Transl Med.
9(90)2011.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Zhang Y, Wilt E and Lu X: Human isogenic
cell line models for neutrophils and myeloid-derived suppressor
cells. Int J Mol Sci. 21(7709)2020.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Fultang L, Panetti S, Ng M, Collins P,
Graef S, Rizkalla N, Booth S, Lenton R, Noyvert B, Shannon-Lowe C,
et al: MDSC targeting with gemtuzumab ozogamicin restores T cell
immunity and immunotherapy against cancers. EBioMedicine.
47:235–246. 2019.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Sheng Y, Duan X, Liu Y, Li F, Ma S, Shang
X, Wang X, Liu Y, Xue R and Qin Z: Tie2-expressing
monocytes/macrophages promote cerebral revascularization in
peri-infarct lesions upon ischemic insult. Signal Transduct Target
Ther. 6(295)2021.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Casacuberta-Serra S, Parés M, Golbano A,
Coves E, Espejo C and Barquinero J: Myeloid-derived suppressor
cells can be efficiently generated from human hematopoietic
progenitors and peripheral blood monocytes. Immunol Cell Biol.
95:538–548. 2017.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Bian Z, Abdelaal AM, Shi L, Liang H, Xiong
L, Kidder K, Venkataramani M, Culpepper C, Zen K and Liu Y:
Arginase-1 is neither constitutively expressed in nor required for
myeloid-derived suppressor cell-mediated inhibition of T-cell
proliferation. Eur J Immunol. 48:1046–1058. 2018.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Zhan X, Hu S, Wu Y, Li M, Liu T, Ming S,
Wu M, Liu M and Huang X: IFN-γ decreased the suppressive function
of CD33+HLA-DRlow myeloid cells through
down-regulation of PD-1/PD-L2 signaling pathway. Mol Immunol.
94:107–120. 2018.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Weber R, Riester Z, Hüser L, Sticht C,
Siebenmorgen A, Groth C, Hu X, Altevogt P, Utikal JS and Umansky V:
IL-6 regulates CCR5 expression and immunosuppressive capacity of
MDSC in murine melanoma. J Immunother Cancer.
8(e000949)2020.PubMed/NCBI View Article : Google Scholar
|
